Quantcast
Last updated on April 18, 2014 at 1:21 EDT

Latest Menorrhagia Stories

2011-03-21 08:00:00

WASHINGTON, March 21, 2011 /PRNewswire/ -- Millions of American women suffer from cyclic heavy menstrual bleeding (HMB), and a recent national survey of more than 1,600 nurse practitioners revealed that this condition has a considerable negative impact on patients' health, lifestyle and even employment. Yet very few patients report their symptoms or request professional help, or they delay reporting their HMB to a medical professional from five months to more than one year, according to...

2011-01-19 13:51:42

Tranexamic acid (TXA), a drug used to treat heavy menstrual periods, could save the lives of tens of thousands of bleeding accident victims each year and reduce combat deaths, say Cochrane researchers. The researchers carried out a systematic review of trials examining the effectiveness of tranexamic acid (TXA) in patients with bleeding after severe injury. TXA is an inexpensive drug that reduces clot breakdown. It has been used for many years to reduce heavy menstrual bleeding and is often...

2011-01-07 06:00:00

BEDFORD, Mass., Jan. 7, 2011 /PRNewswire/ -- Hologic, Inc. (Hologic or the Company) (Nasdaq: HOLX), a leading developer, manufacturer and supplier of premium diagnostics, medical imaging systems and surgical products dedicated to serving the healthcare needs of women, announced today it has acquired Interlace Medical, Inc. (Interlace), the developer and manufacturer of the MyoSure hysteroscopic tissue removal system (MyoSure). Interlace's operations will be integrated within Hologic's GYN...

2010-12-22 15:26:00

MORRISTOWN, N.J., Dec. 22, 2010 /PRNewswire-FirstCall/ -- Watson Pharmaceuticals (NYSE: WPI) today announced the U.S. Food and Drug Administration (FDA) approval of a novel oral contraceptive product - the first and only low dose oral contraceptive to combine 0.8 mg norethindrone and 0.025 mg ethinyl estradiol in chewable form, with four 75 mg ferrous fumarate (iron) placebo tablets. Taken orally, once daily, the product is proven effective in lowering the risk of pregnancy. Watson's new...

2010-12-01 07:00:00

MORRISTOWN, N.J., Dec. 1, 2010 /PRNewswire/ -- Watson Pharmaceuticals, Inc. (NYSE: WPI), announced today that ella® (ulipristal acetate) 30 mg, a novel oral emergency contraceptive, is now available for patients by prescription in the U.S. ella® was approved by the U.S. Food and Drug Administration (FDA) as safe and effective in helping to prevent unintended pregnancy for up to five days after unprotected intercourse (UPI) or a known contraceptive...

2010-11-22 07:00:00

SAN DIEGO, Nov. 22, 2010 /PRNewswire-FirstCall/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced results from the open-label portion of the six month Phase II Daisy PETAL study (901 study) using its proprietary, orally-active nonpeptide Gonadotropin-Releasing Hormone (GnRH) receptor antagonist, elagolix, in patients with endometriosis. "The previously announced improvements across all endometriosis-associated pain domains, during the eight week placebo controlled portion of...

2010-11-09 14:28:00

BEDFORD, Mass., Nov. 9, 2010 /PRNewswire/ -- Booth #410 -- Hologic, Inc. (Hologic or the Company) (Nasdaq: HOLX), a leading developer, manufacturer and supplier of premium diagnostics, medical imaging systems and surgical products dedicated to serving the healthcare needs of women, will showcase its Total Office Solution(TM) at the American Association of Gynecologic Laparoscopists (AAGL) 39th Annual Global Congress of Minimally Invasive Gynecology, November 8-12, 2010, at Caesars Palace...

2010-10-06 08:00:00

PARSIPPANY, N.J., Oct. 6 /PRNewswire/ -- Ferring Pharmaceuticals Inc. today announced publication of one of its pivotal Phase 3 trials of LYSTEDA(TM) (tranexamic acid) tablets for cyclic heavy menstrual bleeding (HMB) in the October issue of the peer-reviewed journal, Obstetrics & Gynecology. The six-month clinical trial demonstrated that LYSTEDA significantly reduced menstrual blood loss from baseline, and improved health-related quality-of-life parameters in women with cyclic HMB...

2010-09-29 13:53:30

Intrauterine devices, originally developed as contraceptives, can also be used to treat and cure cancer of the endometrium according to new research published online in the cancer journal, Annals of Oncology [1] today (Wednesday 29 September). The finding opens the way for young women with the disease, which affects the lining of the womb, to be treated without the need for a hysterectomy, thus preserving their fertility until they have had all the children they want. Endometrial cancer is...

2010-09-14 08:00:00

PARSIPPANY, N.J., Sept. 14 /PRNewswire/ -- Nearly ninety percent of women who experience heavy periods(1) believe their life during their period would greatly improve if they could reduce their menstrual flow, according to a new Harris Interactive® survey commissioned by Ferring Pharmaceuticals. Living With HMB: A National Survey of 500 Women found that many women experience monthly periods that are so heavy they can sap energy, cause anemia, and in many ways interfere...